Carol A Clayberger

Title: The Innovative Contributions of Carol A. Clayberger

Introduction

Carol A. Clayberger is a distinguished inventor based in Stanford, California. She has made significant contributions to the field of antimicrobial research, holding a total of 7 patents. Her work focuses on developing novel peptide-based compounds that have the potential to revolutionize antimicrobial therapies.

Latest Patents

Among her latest patents, Clayberger has developed artificial antimicrobial peptides. These peptides are derived from alterations in the alpha helical portions of a known antimicrobial protein, granulysin. The resulting peptides exhibit significantly improved antimicrobial activity while avoiding the lysis of mammalian cells, which can be toxic to hosts. Additionally, she has created immunomodulating dimers, which are peptide-like compounds with immunomodulating activity. These compounds include variants that are N-terminal acylated and/or C-terminal amidated or esterified, consisting of up to 60 amino acids.

Career Highlights

Clayberger is affiliated with Leland Stanford Junior University, where she continues her research and innovation. Her work has garnered attention for its potential applications in medical science, particularly in combating infections and enhancing immune responses.

Collaborations

Throughout her career, Clayberger has collaborated with notable colleagues, including Alan M. Krensky and Roland Buelow. These partnerships have further enriched her research and contributed to the advancement of her innovative projects.

Conclusion

Carol A. Clayberger's contributions to antimicrobial research exemplify the impact of innovation in the field of medicine. Her patents and ongoing work continue to pave the way for new therapeutic approaches.